Pediatric Perfusion Market (2023 - 2030)

Pediatric Perfusion Market Summary

According to the Centers for Disease Control and Prevention (CDC), approximately 16,800 babies are born each year with a ventricular septal defect, and 1 million children live with a CHD in the U.S. This has led to an increased demand for effective and safe treatment approaches to cure heart defects, and these factors are expected to drive market growth throughout the forecast period. The market is experiencing significant growth primarily due to the surge in the prevalence of respiratory and cardiovascular disease (CVD), the initiatives taken by both government and private organizations to boost organ donations, and the increasing demand for organ transplantation.

For instance, an article published by the American Academy of Pediatrics in 2023 reported that over 1,700 children and adolescents undergo organ transplant procedures in the U.S. annually. Moreover, in 2021, more than 1800 pediatric patients in the U.S. younger than 18 years were awaiting organ transplants. Thus, the rising number of organ transplants is expected to raise the demand for pediatric perfusion systems.

In addition, the rising number of surgical procedures performed on children is expected to drive the market's growth during the forecast period. As medical technologies advance, several surgical procedures are becoming available to treat a wider range of conditions in children. For instance, in 2021, Seattle Children's Hospital performed 746 cardiac procedures and 21 heart transplants. Thus, the growing number of surgeries to cure cardiac conditions boosts the market growth.

Furthermore, the approval of products, partnerships, and strategic acquisitions empower market participants to expand their presence in previously unexplored geographic areas through collaborative efforts and innovation. These companies drive the widespread adoption of modern technologies and enhance the pediatric perfusion industry. For instance, in January 2022, XVIVO received ‘510(k) clearance’ from the U.S. FDA for its portable organ perfusion system, a Kidney Assist Transport. It facilitates donor kidneys' continuous hypothermic pulsatile perfusion using an oxygenated preservation solution throughout the transportation process from the donor to the recipient in transplant procedures.

Product Insights

Based on product, the market is segmented into pediatric oxygenators, pediatric cannulae, pediatric blood pumps, pediatric arterial filters, monitoring systems, and others. The pediatric oxygenators segment held the largest market share of 25.8% in 2022. Oxygenators play a vital role in cardiopulmonary bypass (CPB) procedures, where they eliminate carbon dioxide from the blood while infusing it with oxygen, effectively mimicking the respiratory function of the lungs. This function of oxygenators ensures adequate blood oxygenation, sustaining life throughout the body and its organs is one of the major driving factors in the market.

Furthermore, manufacturers and companies continually develop and introduce innovative and novel oxygenators to improve patient outcomes, efficiency, and safety during CPB procedures. For instance, in November 2021, Micropart Kewei received approval from China's National Medical Products Administration (NMPA) for its Vitasprings Spiral Diversion Integrated Membrane Oxygenator, allowing it to enter the 'Green Path' special approval process designed for innovative medical devices.

The monitoring system segment is projected to grow at the fastest CAGR during the forecast period. The monitoring systems segment in the pediatric perfusion sector drives growth by emphasizing patient safety and benefiting from technological advancements, providing real-time data and feedback during cardiac surgeries. The increasing need for ongoing monitoring, compliance with regulatory standards, and the rising number of cardiac surgeries contribute to the segment's expansion.

End-use Insights

Based on end-use, the market is segmented into hospitals, cardiac centers, and others. The hospitals segment accounted for the largest revenue share of 80.9% in 2022. The rising number of individuals associated with cardiac and respiratory diseases and the growing number of organ transplantation procedures in hospitals drive the market growth. For instance, according to the “2022 Transplant Outcomes Report,” published by STANFORD MEDICINE CHILDREN'S HEALTH, the hospital performed 500+ pediatric heart transplants, 680+ pediatric kidney transplants, 832+ pediatric liver and intestinal transplants, and 85+ pediatric lung and heart-lung transplants. Such factors contribute to the growth of this segment.

The cardiac centers segment is expected to grow significantly during the forecast period, attributed to the rising preference of patients to undergo surgical interventions in cardiac centers. The segment is growing due to the increasing prevalence of cardiovascular diseases and the number of cardiac specialty centers. For instance, in August 2023, according to an article published by the National Center for Biotechnology Information, there were about 5,111 cardiac surgery centers across 230 nations and territories. Thus, the rising number of specialized cardiac centers led to increased patient visits to the centers, further boosting the segment's growth.

Regional Insights

North America dominated the market with the largest share of 41.6% in 2022. Factors such as the region's strong presence of market players, awareness among the public and healthcare stakeholders regarding available technologies, rising incidence of CHD, and well-developed healthcare infrastructure attributed to the market growth. According to the Centers for Disease Control and Prevention (CDC), one in every 240 babies born has a ventricular septal defect in the U.S. In addition, the rise in the number of organ transplant procedures and technological advancements are driving the market in the region.

The Asia Pacific region is expected to experience substantial market growth in the pediatric perfusion sector during the forecast period. This growth can be attributed to advanced healthcare infrastructure and a high prevalence of CVD. Various government initiatives in this region are also anticipated to boost the growth of the market. Furthermore, growing awareness regarding CPB machines, supportive governmental policies, and significant R&D investments contribute to the expansion of the market. Due to these factors, the demand and adoption for CPB machines are increasing, which leads to the overall growth of the market in the region.

Key Companies & Market Share Insights

Key players in the market focus on various strategic initiatives such as acquisitions, mergers, product approval, and collaborations to boost their market presence and overall position in the market. For instance,in September 2022, LivaNova received FDA ‘510(k) clearance’ for its Essenz heart-lung machine (HLM), allowing the company to launch it commercially in the U.S. Essenz HLM has also been approved by Health Canada and the Japanese PMDA. Some prominent players in the global pediatric perfusion market include.

• Medtronic

• LivaNova PLC

• Terumo Cardiovascular Systems Corporation

• BL Lifesciences

• Cardinal Health

• EUROSETS

• Getinge AB

Pediatric Perfusion Market